As of November 10, 2026, AN2 Therapeutics, Inc. is a publicly traded company (Nasdaq: ANTX); its largest reported holder is Commodore Capital, with 9.9% on Schedule 13G of March 16, 2026, then Vivo Opportunity Fund Holdings, L.P. (8%) (Schedule 13G, March 16, 2026).
Is this your company?
About to sign with, pay or invest in AN2 Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is AN2 Therapeutics, Inc. a real, registered company?
- AN2 Therapeutics, Inc. files with the SEC under CIK 1880438 (its SEC filings).
- Its shares are listed under the ticker ANTX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Menlo Park, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under AN2 Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Commodore Capital (filed 2026-03-16).
Who are AN2 Therapeutics, Inc.'s owners and officers?
AN2 Therapeutics, Inc.: incorporated in Delaware; business address in Menlo Park, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-05-15).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-03-25)
- : Executive Officer (Form D, 2026-03-25)
- : Executive Officer (Form D, 2026-03-25)
- : Executive Officer (Form D, 2026-03-25)
- : Director (Form D, 2026-03-25)
- : Director (Form D, 2026-03-25)
- : Director (Form D, 2026-03-25)
- : Director (Form D, 2026-03-25)
- : Director (Form D, 2026-03-25)
- : Director (Form D, 2026-03-25)
- : Director (Form D, 2026-03-25)
- : Director (Form D, 2026-03-25)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-05-15 | Almitas Capital LLC | 4.1% |
| Schedule 13G, 2026-03-16 | Commodore Capital LP | 9.9% |
| Schedule 13G, 2026-03-13 | Millennium Management LLC | 6.3% |
| Schedule 13G, 2026-03-13 | Vivo Opportunity Fund Holdings, L.P. | 8% |
| Schedule 13G, 2026-02-17 | Almitas Capital LLC | 5.4% |
| Schedule 13G/A, 2026-02-13 | Eric Easom | 7.9% |
| Schedule 13G, 2025-11-14 | Almitas Capital LLC | 5.2% |
Questions about who owns AN2 Therapeutics, Inc.
Who owns AN2 Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of AN2 Therapeutics, Inc.: Commodore Capital LP (9.9%, Schedule 13G, filed 2026-03-16), Vivo Opportunity Fund Holdings, L.P. (8%, Schedule 13G, filed 2026-03-13), Eric Easom (7.9%, Schedule 13G/A, filed 2026-02-13) and Millennium Management LLC (6.3%, Schedule 13G, filed 2026-03-13).
Who are the largest shareholders of AN2 Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of AN2 Therapeutics, Inc. on this page are Commodore Capital LP (9.9%), Vivo Opportunity Fund Holdings, L.P. (8%) and Eric Easom (7.9%).
When did Commodore Capital LP buy into AN2 Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Commodore Capital LP on this page is the Schedule 13G, filed 2026-03-16, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on AN2 Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on AN2 Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on AN2 Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own AN2 Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 3,017,432 shares (8.0% of shares outstanding), held indirectly through Holding of BML Investment Partners, L.P. (Form 4, 2025-06-16).
- , a director: 633,842 shares (1.7% of shares outstanding), 9,077 held directly and 624,765 indirectly (Form 4, 2026-09-11).
- , the chief executive and a director: 465,688 shares (1.2% of shares outstanding), 368,630 held directly and 97,058 indirectly (Form 4, 2026-02-23).
- , a director: 439,113 shares (1.2% of shares outstanding), 61,571 held directly and 377,542 indirectly (Form 4, 2026-10-13).
- Joshua Eizen: 207,546 shares (0.55% of shares outstanding) (Form 4, 2026-11-06).
Shares outstanding: 37,943,650 as of 2026-11-05, from the company's latest SEC cover page.
How much has AN2 Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-03-25 | $40M | $40M |
Keep reading
More on AN2 Therapeutics, Inc. and the records around it.
AN2 Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings May 2026
- Form D filing Mar 2026
Companies that share a holder
- Almitas Capital LLC also filed stake reports on 8 other companies: MFS HIGH YIELD MUNICIPAL TRUST (Aug 2026), MFS INVESTMENT GRADE MUNICIPAL TRUST (Aug 2026), ABRDN JAPAN EQUITY FUND, INC. (Feb 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
- Commodore Capital LP also filed stake reports on 40 other companies: Sagimet Biosciences Inc. (Oct 2026), Surrozen, Inc./DE (Oct 2026), JATT III Acquisition Corp (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/an2-therapeutics